{
    "clinical_study": {
        "@rank": "35020", 
        "acronym": "no", 
        "arm_group": [
            {
                "arm_group_label": "Formula or Breast Milk", 
                "arm_group_type": "Active Comparator", 
                "description": "Breast milk or formula prior to every painful procedure."
            }, 
            {
                "arm_group_label": "Multiple doses of sucrose", 
                "arm_group_type": "Active Comparator", 
                "description": "Infants in this group will be  treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of sucrose 24% for pain prevention on\n      preterm infants. Our hypothesis is that repeated doses of sucrose 24%, given prior to\n      painful procedure,do not impair neurodevelopmental outcomes of preterm infants"
        }, 
        "brief_title": "Neurodevelopmental Outcomes of Preterm Infants Treated for Pain Management With Repeated Doses of Sucrose 24%", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Development", 
        "detailed_description": {
            "textblock": "preterm infants born at 27-33 weeks gestational age at Sheba Medical Center will be\n      recruited for this study. Prior to invasive procedure infants will be treated with pacifier\n      and swaddling as recommended by the American Academy of Pediatrics and Canadian Pediatric\n      Society.\n\n      Group 1.Will be treated with Sucrose 24% 0.1-0.5ml on the anterior pat of the tongue 1-3 min\n      prior to invasive procedure.\n\n      Group 2. Similar to group 1 but breast milk or formula will replace Sucrose.\n\n      Number of invasive procedures/day will be documented\n\n      General Movements by Prechtel will be used for developmental assessment at 2,4,6 weeks after\n      birth and at 14-16 weeks corrected age\n\n      Griffiths developmental scales (GMDS) will be used at 40 weeks, 14-16 weeks corrected age,\n      and 3-6 month corrected age"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  preterm infants born at SMC\n\n        Exclusion Criteria:\n\n          -  need for intubation\n\n          -  surgery\n\n          -  need for sedation\n\n          -  abnormal head ultrasound\n\n          -  genetic abnormalities\n\n          -  necrotizing enterocolitis\n\n          -  other painful conditions other than routine blood exams"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "33 Weeks", 
            "minimum_age": "27 Weeks"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742520", 
            "org_study_id": "SHEBA-12-9389-IM-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Multiple doses of sucrose", 
                "description": "unlimited number of doses par day- current status in our NICU", 
                "intervention_name": "multiple doses of sucrose", 
                "intervention_type": "Drug", 
                "other_name": "sucrose 24%"
            }, 
            {
                "arm_group_label": "Formula or Breast Milk", 
                "description": "1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue", 
                "intervention_name": "Formula or breast milk", 
                "intervention_type": "Drug", 
                "other_name": "sucrose 24%"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Preterm infant", 
            "pain", 
            "neurodevelopment"
        ], 
        "lastchanged_date": "June 9, 2013", 
        "location": {
            "contact": {
                "email": "irismorag@gmail.com", 
                "last_name": "Iris Morag, MD", 
                "phone": "+9725307170"
            }, 
            "contact_backup": {
                "last_name": "Tzipora Strauss, MD", 
                "phone": "+9725302227"
            }, 
            "facility": {
                "address": {
                    "city": "Ramat Gan", 
                    "country": "Israel"
                }, 
                "name": "Sheba Medical Center"
            }, 
            "investigator": {
                "last_name": "Iris Morag, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Its an Interventional Study That Will Evaluate the Effect of Different Doses of Sucrose 24% on Neurodevelopmental Outcome of Preterm Infants", 
        "overall_contact": {
            "email": "irismorag@gmail.com", 
            "last_name": "Iris Morag, MD", 
            "phone": "+972526479996"
        }, 
        "overall_contact_backup": {
            "email": "t.tzipi@gmail.com", 
            "last_name": "Tzipi Strauss, MD", 
            "phone": "+97235302215"
        }, 
        "overall_official": {
            "affiliation": "Sheba Medical Center", 
            "last_name": "Iris Morag, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Griffith mental developmental scaled (gross and fine motor, language, performance, social) and General movements by Prechtel", 
            "measure": "neurodevelopmental outcomes", 
            "safety_issue": "No", 
            "time_frame": "at 6 month corrected age"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742520"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Dr. Iris Morag", 
            "investigator_title": "Staff Neonatologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "12205254", 
            "citation": "Johnston CC, Filion F, Snider L, Majnemer A, Limperopoulos C, Walker CD, Veilleux A, Pelausa E, Cake H, Stone S, Sherrard A, Boyer K. Routine sucrose analgesia during the first week of life in neonates younger than 31 weeks' postconceptional age. Pediatrics. 2002 Sep;110(3):523-8."
        }, 
        "secondary_outcome": {
            "description": "Griffith mental developmental scaled (gross and fine motor, language, performance, social) and General movements by Prechtel", 
            "measure": "neurodevelopment", 
            "safety_issue": "No", 
            "time_frame": "at 15 weeks corrected age"
        }, 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}